There are about 15 million people around the world living with drug-resistant epilepsy, about a third of all the people with epilepsy.
This means that their seizures are not controlled by standard anti-seizure medications, and they can often struggle to get clear answers from medical testing.
Current methods of testing usually consist of brief hospital-based monitoring, which is not comprehensive and can often miss seizures, and unreliable diaries kept by patients.
Melbourne-based medtech firm Epiminder is pioneering a world-first implantable device that allows for the continuous brain monitoring of people with epilepsy, while they are able to go about their day-to-day life.
This allows for the better management of drug-resistant epilepsy by enabling more accurate diagnoses and improved treatment planning.
Epiminder has produced a small device that can be placed under the scalp of a patient, that then records brain activity or EEG signals 24 hours a day for months or even years if needed.
Epiminder’s Minder System, which has received FDA approval, includes the sub-scalp implement, wearables, a smartphone app and a secure cloud portal.
This allows for long-term monitoring that can capture events that might be missed by traditional testing methods.
Epiminder is a finalist in the InnovationAus 2025 Awards for Excellence in the Health Tech category. The InnovationAus 2025 Awards for Excellence winners and finalists will be celebrated at a black-tie gala dinner at Sydney Town Hall on Thursday, November 27. You can book your tickets here.
The Health Tech Award honours companies that are tackling global health challenges through new platforms, medical devices, diagnostics, therapeutics and biotech innovations.
Epiminder was founded by the Bionics Institute, Cochlear, St Vincent’s Hospital and the University of Melbourne, and commercialised the research of Professor Mark Cook.
Epiminder vice president of market access Chip Moebus said the awards nomination is a “tremendous honour” for the company, and a “powerful acknowledgement of the collective vision, dedication and ingenuity behind the Minder System”.
“This nomination speaks not only to our technical innovation but also to our core mission: empowering people living with epilepsy through real-world, continuous brain monitoring that can transform clinical care and daily life,” Mr Moebus said.
“For our team, this recognition validates years of collaboration with clinicians, engineers, people with epilepsy and their families.
“Being shortlisted among Australia’s top innovators inspires us to drive deeper partnerships, reach more patients and continue pushing boundaries in neurotechnology. Above all, this nomination amplifies the voices of people with epilepsy, shining a national spotlight on their needs, hopes and resilience.
“It motivates Epiminder to keep striving for clinical excellence, technology leadership, and a future where epilepsy is better understood and ultimately, better managed.”
The 2025 InnovationAus Awards for Excellence will be held on November 27 at the magnificent Sydney Town Hall. You can secure individual seats or book a table here. Purchase a table of 10 and have your logo displayed on screens across the venue and in the event programme as a ‘Table Sponsor’.
The InnovationAus 2025 Awards for Excellence are proudly supported by ACS, PEXA Group, the CSIRO ON Program, Griffith Hack, TechnologyOne, Q-CTRL, National AI Centre, University of New South Wales, KPMG, AgriFutures Australia, Investment NSW and IP Australia.
Protecting your great ideas with intellectual property (IP) rights can lead to lasting benefits for your growing business. IP refers to creations of the mind, such as a brand, logo, invention, design or artistic work. Head to the IP Australia website to find out more about IP, and how it might help your business.
Do you know more? Contact James Riley via Email.